Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
Davide Fiore Bavaro; Alessandra Belati; Lucia Diella; Monica Stufano; Federica Romanelli; Luca Scalone; Stefania Stolfa; Luigi Ronga · 2021 · Antibiotics
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as “rescue” treatments in immunocompromised or critically ill patients or in patients with post-surgical infections who had failed previous regimens. A total of 13 patients were treated from 1 September 2020 to 31 March 2021. In total, 5/13 (38%) patients were classified as critically ill, due to severe COVID-19 lung failure; 4/13 (31%) patients had post-surgical infections and 4/13 (31%) had severe infections in immunoc
Abstract by Davide Fiore Bavaro; Alessandra Belati; Lucia Diella; Monica Stufano; Federica Romanelli; Luca Scalone; Stefania Stolfa; Luigi Ronga, Antibiotics (2021) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Power and Predictive Accuracy of Polygenic Risk Scores
Negative / Null Result ReportLocoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases
Negative / Null Result ReportCritical aspects of using bacterial cell viability assays with the fluorophores SYTO9 and propidium iodide
Negative / Null Result ReportAlpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Negative / Null Result ReportA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy
Negative / Null Result ReportThe CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.3390/antibiotics10060652